

Special Issue

Mitochondria as Potential Target in Disease Therapy

Message from the Guest Editors

The current special issue is designated to publish original articles investigating mitochondria as a therapeutic target in diseases because relevance of the impairment in this organelle in metabolism, immunity, apoptosis, and signal transduction alterations.

Mitochondria are highly dynamic organelles that have a critical role in ROS production, cross talking between redox signaling and metabolic regulation, in cell death regulation and calcium homeostasis. Thus, mitochondria impairment plays a pivotal role in the genesis and development of acute and chronic injuries, triggering pathological pathways like inflammation, oxidative stress and fibrosis. Furthermore, recent use of mitochondrial target therapies has showed promising results in resolve or prevent different pathologies.

Therefore, we invite investigators to submit an original research paper or review articles for publication in this Special issue. We are particularly interested in articles related to mitochondrial improvement in diseases such as metabolic diseases, cancer, kidney diseases, hepatic diseases, heart diseases, and more.

Guest Editors

Prof. Dr. José Pedraza Chaverri

Prof. Dr. Cecilia Zazueta

Dr. Omar Emiliano Aparicio Trejo

Deadline for manuscript submissions

closed (10 December 2022)



Future Pharmacology

an Open Access Journal
by MDPI

Impact Factor 2.7



mdpi.com/si/109251

Future Pharmacology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
future-
pharmacology@mdpi.com

[mdpi.com/journal/
futurepharmacol](https://mdpi.com/journal/futurepharmacol)





Future Pharmacology

an Open Access Journal
by MDPI

Impact Factor 2.7



[mdpi.com/journal/
futurepharmacol](https://mdpi.com/journal/futurepharmacol)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Fabrizio Schifano
Psychopharmacology, Drug Misuse and Novel Psychoactive
Substances Research Unit, School of Life and Medical Sciences,
University of Hertfordshire, Hertfordshire AL10 9AB, UK

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid
by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), EBSCO, and other
databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy)